We initially found that expression of MUC1-C and A3A, but not A3B, is significantly increased in H1975 NSCLC cells treated with the EGFR TKI osimertinib (OSI) (Figs. 1A and S1A). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.